The FDA has issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), marking the first treatment for adults and children aged 8 years and older with glycogen storage disease type Ia (GSDIa).
The FDA has issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr), marking the first treatment for adults and children aged 8 years and older with glycogen storage disease type Ia (GSDIa).